Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc. on June 6, 2017, reporting events occurring on June 6 and June 8, 2017. The filing details a change in corporate headquarters, the transfer of a lease to a third party, and the resignation of the Chairman of the Board.
Key Financial Metrics and Agreements
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics. However, it discloses specific contractual financial terms:
- New Lease Cost: $8,294 per month for the new headquarters at 750 Third Avenue, New York, NY.
- Lease Term: Expires January 31, 2018.
- License Income: $7,529 per month received from Actinium Pharmaceuticals, Inc. for the use of furniture, fixtures, and equipment (FFE) at the former headquarters.
- License Term: Contemporaneous with the new lease term.
Material Changes
- Headquarters Relocation: The Company moved its principal executive offices from 275 Madison Avenue to 750 Third Avenue, New York, NY.
- Lease Assignment: The Company transferred its lease for the former headquarters (275 Madison Avenue) to Actinium Pharmaceuticals, Inc.
- Board Resignation: Sandesh Seth resigned as Director and Chairman of the Board to focus on external matters. The resignation was not due to any disagreement regarding company operations.
- Executive Compensation Adjustment: Upon resignation, all of Mr. Seth's outstanding stock options became 100% vested. He will continue as a consultant until December 31, 2017.
Outlook, Risks, and Management Commentary
Management commentary is limited to the operational details of the lease transfer and the amicable nature of the Chairman's departure. The filing notes that the Company entered into an Amended and Restated License Agreement with Actinium, granting Actinium the right to purchase the FFE at any time during the term. No specific forward-looking guidance, risk factors, or contingencies beyond the standard lease and consulting terms are disclosed in this report.
Investor Verification Checklist
- Verify the net impact of the new lease cost ($8,294) versus the license income ($7,529) on monthly operating expenses.
- Confirm the status of the Board of Directors following the resignation of the Chairman and whether a replacement has been appointed.
- Review the upcoming Form 10-K for the full text of the Lease Agreement, License Agreement, and the Advisory and Consulting Agreement with Mr. Seth.
- Assess the strategic rationale for the headquarters move and the relationship with Actinium Pharmaceuticals, Inc.